ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells $1,095,442.53 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 16,809 shares of the business’s stock in a transaction on Friday, April 19th. The stock was sold at an average price of $65.17, for a total value of $1,095,442.53. Following the completion of the sale, the chief operating officer now directly owns 782,620 shares in the company, valued at $51,003,345.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Muthusamy Shanmugam also recently made the following trade(s):

• On Wednesday, April 17th, Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.40, for a total value of $622,608.00.
• On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total value of $491,770.62.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total value of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.

ANI Pharmaceuticals Stock Down 1.1 %

ANIP stock opened at $65.43 on Thursday. ANI Pharmaceuticals, Inc. has a fifty-two week low of $36.99 and a fifty-two week high of $70.81. The business’s 50-day moving average is $65.34 and its two-hundred day moving average is $58.75. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57. The company has a market cap of $1.38 billion, a price-to-earnings ratio of 77.89 and a beta of 0.79.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The company had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ANIP shares. Truist Financial upped their price target on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 1st. Guggenheim reaffirmed a “buy” rating and set a $77.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday. Capital One Financial started coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 price target on the stock. Finally, HC Wainwright upped their price target on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $80.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in ANI Pharmaceuticals by 5.4% in the third quarter. Vanguard Group Inc. now owns 1,132,378 shares of the specialty pharmaceutical company’s stock valued at $65,746,000 after acquiring an additional 58,204 shares during the period. Rubric Capital Management LP increased its position in ANI Pharmaceuticals by 32.8% in the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after buying an additional 277,989 shares in the last quarter. Dimensional Fund Advisors LP increased its position in ANI Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock worth $32,628,000 after buying an additional 33,359 shares in the last quarter. Global Alpha Capital Management Ltd. increased its position in ANI Pharmaceuticals by 10.8% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock worth $32,115,000 after buying an additional 56,900 shares in the last quarter. Finally, Ranger Investment Management L.P. increased its position in ANI Pharmaceuticals by 1.8% in the fourth quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock worth $23,965,000 after buying an additional 7,769 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.